Lopez L M, Mehta J L
Am J Cardiol. 1984 Mar 1;53(6):787-90. doi: 10.1016/0002-9149(84)90405-3.
The comparative efficacy and safety of lofexidine and clonidine in patients with mild to moderate systemic hypertension were evaluated. Patients who met established criteria were administered lofexidine or clonidine in a double-blind manner. The dose of either drug, along with hydrochlorothiazide if necessary, was titrated to blood pressure response or to the occurrence of side effects. Treatment with the dose established during titration was continued for 12 weeks. Blood pressure and the occurrence of side effects were evaluated during weekly clinic visits. Twenty-six patients completed all portions of the study. The decrease in blood pressure compared with that with the placebo was significant for both drugs (p less than 0.05). The daily dose of clonidine required for blood pressure control was less than that of lofexidine (p less than 0.05). Concomitant diuretic therapy was required equally as often for both drugs. Clonidine caused adverse effects more frequently than did lofexidine. The effectiveness of lofexidine is comparable to that of clonidine, but lofexidine has a lower incidence of toxicity.
评估了洛非西定和可乐定在轻至中度系统性高血压患者中的相对疗效和安全性。符合既定标准的患者以双盲方式服用洛非西定或可乐定。必要时，两种药物的剂量以及氢氯噻嗪的剂量会根据血压反应或副作用的发生情况进行调整。滴定过程中确定的剂量治疗持续12周。在每周的门诊就诊时评估血压和副作用的发生情况。26名患者完成了研究的所有部分。两种药物与安慰剂相比，血压下降均具有显著性（p小于0.05）。控制血压所需的可乐定每日剂量低于洛非西定（p小于0.05）。两种药物同等频繁地需要联合利尿治疗。可乐定引起不良反应的频率高于洛非西定。洛非西定的有效性与可乐定相当，但洛非西定的毒性发生率较低。
